Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
The stock has had a mixed run, with a 70.5% return over the past year and 40.1% over three years, alongside a 26.3% year to date decline, including 16.4% over the last month and 18.7% over the last week. These recent moves have come in the context of ongoing attention on Travere Therapeutics and its pipeline in rare disease treatments, as investors reassess how future prospects line up with the current share price. That backdrop helps explain why the stock can shift quickly as new information feeds into expectations. On Simply Wall St's 6 point valuation framework, Travere Therapeutics has a value score of , which we will break down using several common valuation approaches, before finishing with a way of looking at valuation that many investors may find even more useful. Travere Therapeutics delivered 70.5% returns over the last year. See how this stacks up to the rest of the Biotechs industry. A Discounted Cash Flow, or DCF, model estimates what a company might be worth tod
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law FirmBusiness Wire
- Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential [Seeking Alpha]Seeking Alpha
- INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLCGlobeNewswire
- TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 1/13/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- TVTX's page on the SEC website